Keywords: Trubion, Emergent BioSolutions, M&A, Fiancial guidance, Oncology, Autoimmunity
Emergent BioSolutions to buy Trubion Pharma for up to $135.5 million; reaffirms 2010 guidance
Article | 16 August 2010
US vaccine maker Emergent BioSolutions has entered into a definitive agreement to acquire Trubion Pharmaceuticals, for upfront consideration of $96.8 million ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
